Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs
Portfolio Pulse from Vandana Singh
Johnson & Johnson (JNJ) is changing its 340B Drug Pricing Program policy for its drugs Stelara and Xarelto. Starting October 15, hospitals must buy these drugs at full price and submit data to receive a rebate. The AHA has raised concerns about the policy's compliance with the 340B statute.
August 26, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Johnson & Johnson is implementing a new policy for its 340B Drug Pricing Program, affecting its drugs Stelara and Xarelto. Hospitals must purchase these drugs at full price and submit data for rebates. The AHA has expressed concerns about the policy's compliance with the 340B statute.
The new policy could impact JNJ's relationship with hospitals and its compliance with the 340B statute, but the immediate financial impact on JNJ is unclear. The stock price may remain stable in the short term as the market assesses the implications.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100